Special Issues and Supplements

March 2021 Clinical Trials to Clinical Practice
2020 Year in Review: Non–Small-Cell Lung Cancer
AONN+ 2020 Conference Highlights Special Feature
2020 Year in Review - Cholangiocarcinoma
2020 Year in Review - Ovarian Cancer
2020 Year in Review - Neuroendocrine Tumors
2020 Year in Review - Breast Cancer
2020 Year in Review - Biosimilars
2020 Year in Review - Multiple Myeloma
Faculty Perspectives: Current Guidelines and Emerging Treatments in Nonmetastatic NSCLC
June 2020 Clinical Trials to Clinical Practice
Faculty Perspectives: PI3K Inhibitors: Efficacy in Hematologic Malignancies and Management of Treatment-Related Adverse Events
Best Practices in Patient Navigation – The Role of Oncology Nurse Navigators in Hepatocellular Carcinoma Treatment
Best Practices in Hematologic Malignancies – December 2019 Vol 10
Best Practices in Lung Cancer – November 2019 Vol 10 – Filling an Educational Void
2019 Fourth Annual Oncology Guide to New FDA Approvals
Best Practices in Patient Navigation – Navigating Hematologic Malignancies
Faculty Perspectives: Next-Generation Sequencing Testing in Oncology | Part 4 of a 4-Part Series
Best Practices in Immuno-Oncology Biomarker Testing December 2018 | Part 4 of a 4-Part Series
Best Practices in Lung Cancer – November 2018 Vol 9
Faculty Perspectives: Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors | Part 3 of a 4-Part Series
Best Practices in Breast Cancer – October 2018 Vol 9
Best Practices in Immuno-Oncology Biomarker Testing – October 2018 | Part 3 of a 4-Part Series
Best Practices in Immuno-Oncology Biomarker Testing – September 2018 | Part 2 of a 4-Part Series
Faculty Perspectives: Rationale for PD-L1 Expression as a Biomarker in Immuno-Oncology | Part 2 of a 4-Part Series
Best Practices in Immuno-Oncology Biomarker Testing - August 2018 | Part 1 of a 4-Part Series
Faculty Perspectives: An Overview of Existing and Emerging Biomarkers in Oncology | Part 1 of a 4-Part Series
Rx Profiler – Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
2018 Third Annual Oncology Guide to New FDA Approvals
Best Practices in Immunotherapy – June/July 2017 Vol 8
Page 1 of 2
Results 1 - 30 of 40

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code